Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
Marrow Therapeutics is unveiling with $173 million in combined series A and B cash to fuel its efforts to create…
Marrow Therapeutics is unveiling with $173 million in combined series A and B cash to fuel its efforts to create…